Inhibition of RANKL-Induced Osteoclastogenesis by (−)-DHMEQ, a Novel NF-κB Inhibitor, Through Downregulation of NFATc1

Abstract

The inhibition of NF-kappaB suppresses osteoclastogenesis by downregulation of NFATc1, suggesting that NFATc1 expression is regulated by NF-kappaB in RANKL-induced osteoclastogenesis. Our results also indicate the possibility of (-)-DHMEQ becoming a new therapeutic strategy against bone erosion.